Otsuka makes pipeline changes; Oculis reveals $100M offering
Plus, news about Aardvark’s IPO: Otsuka cuts cancer programs: The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated several cancer ...
Plus, news about Aardvark’s IPO:
Otsuka cuts cancer programs: The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated several cancer ...
